Poor sales trajectory, check. Scale-back in marketing effort, check. What’s next for Valeant’s Addyi and its maker, Sprout? An impairment charge, if you ask…

With brand-new hiked-up sales forecasts for its newest meds, Bayer is hoping for a home run from prostate cancer-fighter Xofigo--and it's counting on a…

Sanofi and Regeneron’s next wannabe blockbuster is officially in regulators’ hands--but with the candidate tapped for a speedy review process, it may not stay…

New meds are encroaching on a corner of the market for Novartis’ broader severe asthma treatment Xolair. But in response, the company is making it easier to…

Amgen’s Humira biosimilar is now officially FDA-approved. It has an official brand name, Amjevita. But that doesn’t mean it will come to a pharmacy near you…

Vanda is a small drugmaker. Its two central nervous system drugs generated only about $100 million in sales last year. But with lots of M&A dollars being…

Novartis has some new data in hand that could potentially help cancer med Zykadia snag a first-line indication in ALK+ non-small cell lung cancer. But a rival…

After Sarepta Therapeutics this week won FDA approval for its controversial Duchenne muscular dystrophy drug, the CEO assured analysts it has a plan to ramp up…